Pancreatic cancer success story stems from 'undruggable' KRAS target
statnews.com • • business
Key Points:
- Leanna Stokes, diagnosed with metastatic pancreatic cancer featuring a KRAS gene mutation, found hope in emerging targeted treatments after multiple chemotherapy lines.
- KRAS mutations have long been challenging to drug effectively, with early inhibitors showing only marginal improvements and rapid resistance in patients.
- The discovery by biochemist Kevan Shokat paved the way for new KRAS-targeting drugs, leading to increased pharmaceutical interest and numerous clinical trials.
- Revolution Medicines' drug daraxonrasib, which targets KRAS and related proteins, significantly extended Stokes' life and is generating excitement for its potential in treating pancreatic and other KRAS-mutant cancers.
- The development of KRAS inhibitors marks a promising new era in oncology, with many companies actively pursuing therapies for various cancers driven by KRAS mutations.
 { path { fill: %23EEEFE9 } })